ZebraBioRes

04/02/2025

El grupo Zebra BioRes incorpora un tipo de pez killi que se utiliza para esos proyectos al tener una vida de solo entre 4 y 6 meses. El equipo que lidera Laura Sánchez Piñón ha trasladado su acuario al Cebiovet, donde duplica su superficie

28/10/2022

'O grupo Acuigen da USC ensaia en peixe cebra un composto velenoso dun polbo australiano que frea o melanoma mutado por BRAF'

Os investigadores da área de Xenética na Facultade de Veterinaria do Campus Terra Laura Sánchez, Pablo Cabezas Sainz e Sabela Fernández Vila probaron nun modelo ‘in vivo’ os efectos terapéuticos do péptido ao abeiro dun proxecto internacional liderado por María Ikonomopoulou, do IMDEA, se...

17/04/2021

'Pelayo and zebrafish helping in rare diseases research'

The main goal of our project is to develop, through CRISPR-Cas9 genetical edition technology, a zebrafish model useful for the study of “ultra-rare” diseases with extremely limited number of patients, for which the capability of a mutation to induce a disease needs confirmation. For such, a CDG subtype associated to a mutation in the RFT1 gene. From this point, a model will be available for studying the potential triggering factors, histologic, metabolic or physiological changes, and for testing specific treatments.

Only one patient with this mutation is known in Spain: Pelayo, a small two-year old superheroe who fights for carrying on and hopes for a small genetically modified fish to bring light to this disease and contribute to the pursuit of a treatment for affected children. This is not science-fiction! Several rare diseases have found a cure through similar strategies.

Congenital Disorders of Glycolysation (CDG) are severe and very rare diseases with a prevalence between 1/50.000 and 1/100.000

07/04/2021

'Noticia de Lugo: Investigación tumor cerebral con pez cebra', ¡en el cuál está implicado el equipo de ZebraBioRes! ¡Enhorabuena a todos los integrantes!

27/10/2020

'Zebrabiores helps to get a deep understanding of pancreatic cancer using zebrafish model'

Pancreatic cancer, specifically pancreatic ductal adenocarcinoma (PDAC), its nowadays one of the pancreatic tumors with the worst prognostic. It represents the fourth cause of death due to cancer, with a survival rate of 7-9% within the next 5 years since the diagnostic.One of the factors that could...

25/09/2018

Our PhD Student Pablo Cabezas gave a talk in the i3s research center in Oporto by the invitation of Jose Bessa.The title of the talk was "Zebrafish avatars: a new ‘tiny’ weapon against cancer?" being a summary of his PhD thesis in the last 4 years, presenting results related to the improve of th...

17/09/2018

Ya está aquí , la 1ªde 2018! El 27/09 tienes una cita con de Ciencia! Podrás verlo en Santiago en directo o 📡 desde casa por streaming!
👉¿Es la energía nuclear una opción válida y segura?
📅 Jueves 27 de septiembre
⏰ 20.00h
🗺 Fac. Comunicación USC

17/08/2018

A month ago, PhD students Álvaro Arana and Carlos Coppel made a brief two-week stay in the José Bessa group, Vertebrate Development and Regeneration, of the Instituto de Investigação e Inovação of the University of Porto (i3S). There, they learned new molecular techniques to carry out their in...

01/08/2018

Zebrabiores group attended at the 10th Annual NGS & Clinical Diagnostics Congress in Warsaw, Poland. In this congress, PhD student Carlos Coppel, PhD student Alvaro Arana, PhD student Alba Pensado, PhD student Ana Quelle, PhD student Andrés Blanco presented a poster titled "Metaanalysis of differen...

18/07/2018

18/07/2018

NOP56 is the key. We know where is the mutation that share all the people affected by this disease, SCA36, or Dead Cost Ataxia. The symptoms of this disease are known (lose of balance and audition, problems to talk or walk) but we still do not know which is the mechanism for this mutation to cause a...